Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0LYIPC
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Inebilizumab-amanitin
|
|||||
| Synonyms |
Inebilizumab amanitin
Click to Show/Hide
|
|||||
| Organization |
LegoChem Biosciences, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Burkitt lymphoma [ICD11:2A85]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Inebilizumab
|
Antibody Info | ||||
| Antigen Name |
B-lymphocyte antigen CD19 (CD19)
|
Antigen Info | ||||
| Payload Name |
Alpha-amanitin
|
Payload Info | ||||
| Therapeutic Target |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
|
Target Info | ||||
| Linker Name |
Inebilizumab-amanitin linker
|
|||||
| Conjugate Type |
Site-specific conjugation through the CaaX sequence at the C-terminal.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.